SIREN : 845183110
ZYMOPTIQ is a French company founded 7 years ago, specialized in the sector Activités spécialisées, scientifiques et techniques diverses. Based in LEZENNES (59260), this company of category PME shows in 2022 a revenue of 140 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | N/C | N/C | 140 396 € | N/C |
| Net income | 0 € | 0 € | -440 631 € | 0 € |
| EBITDA | N/C | N/C | -457 319 € | N/C |
| Net margin | N/C | N/C | -313.8% | N/C |
In 2024, ZYMOPTIQ records a net loss of 0 €. This deficit will reduce equity on the balance sheet.
The debt ratio (= Financial debt / Equity x 100) stands at 94%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
93.837%
44.392%
67.4%
In 2024, the debt ratio of ZYMOPTIQ (93.84) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of ZYMOPTIQ (44.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2022, the repayment capacity of ZYMOPTIQ (-11.08) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 594.16. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
594.157
In 2024, the liquidity ratio of ZYMOPTIQ (594.16) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2022, the interest coverage of ZYMOPTIQ (-10.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 342 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 459 days. Excellent situation: suppliers finance 117 days of the operating cycle (retail model).
0 €
342 j
459 j
0 j
Compare ZYMOPTIQ with other companies in the same sector:
Voir toutes les statistiques du secteur Activités spécialisées, scientifiques et techniques diverses
The revenue of ZYMOPTIQ in 2022 is 140 k€.
ZYMOPTIQ recorded a net loss in 2022.
The headquarters of ZYMOPTIQ is located in LEZENNES (59260), in the department Nord.
The tax return of ZYMOPTIQ is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ZYMOPTIQ operates in the sector Activités spécialisées, scientifiques et techniques diverses (NAF code 74.90B). See the 'Sector positioning' section above to compare the company with its competitors.